Adaptive designs for identifying optimal biological dose for molecularly targeted agents

Background Traditionally, the purpose of a dose-finding design in cancer is to find the maximum tolerated dose based solely on toxicity. However, for molecularly targeted agents, little toxicity may arise within the therapeutic dose range and the dose–response curves may not be monotonic. This challenges the principle that more is better, which is widely accepted for conventional chemotherapy. Methods We propose three adaptive dose-finding designs for trials evaluating molecularly targeted agents, for which the dose–response curves are unimodal or plateaued. The goal of these designs is to find the optimal biological dose, which is defined as the lowest dose with the highest rate of efficacy while safe. The first proposed design is parametric and assumes a logistic dose–efficacy curve for dose finding, the second design is nonparametric and uses the isotonic regression to identify the optimal biological dose, and the third design has the spirit of a ‘semiparametric’ approach by assuming a logistic model only locally around the current dose. Results We conducted extensive simulation studies to investigate the operating characteristics of the proposed designs. Simulation studies show that the nonparametric and semiparametric designs have good operating characteristics for finding the optimal biological dose. Limitations The proposed designs assume a binary endpoint. Extension of the proposed designs to ordinal and time-to-event endpoints is worth further investigation. Conclusion Among the three proposed designs, the nonparametric and semiparametric designs yield consistently good operating characteristics and thus are recommended for practical use. The software to implement these two designs is available for free download at http://odin.mdacc.tmc.edu/~yyuan/.

[1]  Shyamal D Peddada,et al.  Designs for Single‐ or Multiple‐Agent Phase I Trials , 2004, Biometrics.

[2]  Wei Zhang,et al.  An adaptive dose‐finding design incorporating both toxicity and efficacy , 2006, Statistics in medicine.

[3]  D H Leung,et al.  Isotonic designs for phase I trials. , 2001, Controlled clinical trials.

[4]  Ying Kuen Cheung,et al.  Two‐Stage Designs for Dose‐Finding Trials with a Biologic Endpoint Using Stepwise Tests , 2008, Biometrics.

[5]  Edward L Korn,et al.  Dose escalation trial designs based on a molecularly targeted endpoint , 2005, Statistics in medicine.

[6]  P. Grambsch,et al.  Modeling Survival Data: Extending the Cox Model , 2000 .

[7]  Razelle Kurzrock,et al.  Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse , 2010, Clinical Cancer Research.

[8]  F. T. Wright,et al.  Order restricted statistical inference , 1988 .

[9]  Zhilong Yuan,et al.  Isotonic designs for phase I cancer clinical trials with multiple risk groups , 2004, Clinical trials.

[10]  T. Turner,et al.  Locating a maximum using isotonic regression , 1997 .

[11]  M. G. Pittau,et al.  A weakly informative default prior distribution for logistic and other regression models , 2008, 0901.4011.

[12]  Ying Yuan,et al.  BAYESIAN DATA AUGMENTATION DOSE FINDING WITH CONTINUAL REASSESSMENT METHOD AND DELAYED TOXICITY. , 2013, The annals of applied statistics.

[13]  J. M. Bremner,et al.  Statistical Inference under Restrictions , 1973 .

[14]  A. Reynolds,et al.  Potential Relevance of Bell-Shaped and U-Shaped Dose-Responses for the Therapeutic Targeting of Angiogenesis in Cancer , 2010, Dose-response : a publication of International Hormesis Society.

[15]  Edward L Korn,et al.  Nontoxicity endpoints in phase I trial designs for targeted, non-cytotoxic agents. , 2004, Journal of the National Cancer Institute.

[16]  Stephen B. Kaye,et al.  Clinical benefit in phase I trials of novel molecularly targeted agents: Does dose matter? , 2008 .

[17]  Johann S de Bono,et al.  Early oncology clinical trial design in the era of molecular-targeted agents. , 2010, Future oncology.

[18]  Daniel J Sargent,et al.  Model‐based phase I designs incorporating toxicity and efficacy for single and dual agent drug combinations: Methods and challenges , 2010, Statistics in medicine.

[19]  Lesley Seymour,et al.  An Overview of the Optimal Planning, Design, and Conduct of Phase I Studies of New Therapeutics , 2010, Clinical Cancer Research.

[20]  J. Lee,et al.  Dose Escalation Methods in Phase I Cancer Clinical Trials , 2009, Journal of the National Cancer Institute.

[21]  Antje Hoering,et al.  Seamless Phase I-II Trial Design for Assessing Toxicity and Efficacy for Targeted Agents , 2010, Clinical Cancer Research.

[22]  E. Eisenhauer,et al.  Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. , 2004, Journal of the National Cancer Institute.